This study will examine the efficacy, safety, and effect on hemoglobin levels, of once weekly epoetin beta subcutaneous injections (30,000 International Units \[IU\]) in anemic patients with solid tumors. The anticipated study duration is 4 months, and the target sample size is 40 individuals.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
10
Dosage at Initiation: Subcutaneous injection of 30000 IU administered once a week. Dosage could be increased to 30000 IU twice a week or 60000 IU once a week after 4 weeks if a blood transfusion was required or hemoglobin level did not increase by at least 0.5 grams per deciliter (g/dL) versus baseline.
Unnamed facility
Caracas, Venezuela
Unnamed facility
Valencia, Venezuela
Hemoglobin Levels at 16 Weeks
Time frame: 16 Weeks
Serum Iron Levels
Time frame: 16 Weeks
Quality of Life According to Functional Assessment of Cancer Therapy - Anemia (FACT-An) Instrument
Time frame: Up to 4 months
Tolerability - Incidence of Adverse Events
Time frame: Up to 4 months
Serum Transferrin Levels
Time frame: 16 Weeks
Percentage of Participants With A Positive Response
Time frame: 16 Weeks
Time To Global Response
Time frame: Up to 4 months
Quality of Life In Relation to Anemia Grade
Time frame: Up to 4 months
Serum Ferritin Levels
Time frame: 16 Weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.